Medicare keeps drug negotiation in place until rivals sell

For Medicare Part D enrollees, the practical question is when a negotiated drug finally stops carrying the government-set price. CMS says the answer is not the day a generic or biosimilar wins approval. The new competition has to be marketed before the selected drug can leave negotiation, which means negotiated pricing can keep running after the FDA clears a rival product.

That matters because a selected drug remains in the program for its initial price applicability year and for later years that fall inside the timing window CMS sets out. In plain English, the price floor does not disappear just because another version has been approved on paper.

Approval is not the finish line

CMS is building a real-world competition test into the Medicare Drug Price Negotiation Program. A selected drug keeps its status until the agency determines it has ceased to be subject to negotiation, and even then the exit does not fully take hold until the first year that begins at least nine months later. CMS will publish the deselection decision once that point is reached.

The rule is meant to track market entry, not just regulatory paperwork. A generic or biosimilar can be approved and still not count as the kind of competition that ends Medicare’s negotiated price treatment if it has not actually reached the market.

Why the lag matters

That lag can matter for patients filling prescriptions, for plans deciding what to cover and for manufacturers watching when negotiated prices finally give way to ordinary competition. Until deselection takes effect, the selected drug can stay under the Medicare price umbrella even after a rival product exists.

The result is a simpler rule with a sharper edge: approval opens the door, but marketing and timing decide when Medicare walks through it. For drugs that have been selected for negotiation, that delay can be the difference between one more year of controlled pricing and a clean exit from the program.